Metabolic syndrome

Dermatologic Therapy

Volumn 21, Issue 5, 2008, Pages 362-375

  Lien, Lillian F ^a   Guyton, John R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; Hirsutism; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; RAMIPRIL; SIBUTRAMINE; SITAGLIPTIN; SPIRONOLACTONE; SULFONYLUREA; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADIPOCYTE; CHOLESTEROL BLOOD LEVEL; DIAGNOSTIC TEST; DYSLIPIDEMIA; ENDOCRINE GLAND; HIRSUTISM; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; MEDICAL SOCIETY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WORLD HEALTH ORGANIZATION;

HIRSUTISM; HUMANS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 53349097257     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2008.00218.x     Document Type: Review

References (114)

1. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004:291:2847 2850.
2. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002:288:1723 1727.
3. Kuczmarski RJ, Carroll MD, Flegal KM, et al. Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994). Obes Res 1997:5:542 548.
4. Kuczmarski RJ, Flegal KM. Criteria for definition of overweight in transition: background and recommendations for the United States. Am J Clin Nutr 2000:72:1074 1081.
5. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006:295:1549 1555.
6. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999:341:427 434.
7. State-specific prevalence of obesity among adults - United States, 2005. MMWR Morb Mortal Wkly Rep 2006:55:985 988.
8. Flegal KM, Graubard BI, Williamson DF, et al. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005:293:1861 1867.
9. Mokdad AH, Marks JS, Stroup DF, et al. Actual causes of death in the United States, 2000. JAMA 2004:291:1238 1245.
10. Mokdad AH, Marks JS, Stroup DF, et al. Correction: actual causes of death in the United States, 2000. JAMA 2005:293:293 294.
11. Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med 2002:80:696 702.
12. Muennig P, Lubetkin E, Jia H, et al. Gender and the burden of disease attributable to obesity. Am J Public Health 2006:96:1662 1668.
13. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005:352:1138 1145.
14. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006:355:763 778.
15. Kannel WB, D'Agostino RB, Cobb JL. Effect of weight on cardiovascular disease. Am J Clin Nutr 1996:63:419S 22S.
16. Yan LL, Daviglus ML, Liu K, et al. Midlife body mass index and hospitalization and mortality in older age. JAMA 2006:295:190 198.
17. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988:37:1595 1607.
18. Miranda PJ, DeFronzo RA, Califf RM, et al. Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J 2005:149:33 45.
19. Ford ES. Prevalence of the metabolic syndrome in US populations. Endocrinol Metab Clin North Am 2004:33:333 350.
20. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002:287:356 359.
21. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003:108:1541 1545.
22. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005:366:1059 1062.
23. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998:15:539 553.
24. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999:16:442 443.
25. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003:9:237 252.
26. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American heart association council on nutrition, physical activity, and metabolism: endorsed by the american college of cardiology foundation. Circulation 2004:110:2952 2967.
27. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001:285:2486 2497.
28. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005:28:2289 2304.
29. Bruno G, Merletti F, Biggeri A, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004:27:2689 2694.
30. Stern MP, Williams K, Gonzalez-Villalpando C, et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004:27:2676 2681.
31. Grundy SM. Does the metabolic syndrome exist? Diabetes Care 2006:29:1689 1692 discussion 93-96.
32. Natali A, Ferrannini E. Hypertension, insulin resistance, and the metabolic syndrome. Endocrinol Metab Clin North Am 2004:33:417 429.
33. Saely CH, Aczel S, Marte T, et al. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 2005:90:5698 5703.
34. Wassink AM, van der Graaf Y, Olijhoek JK, et al. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2008:29:213 223.
35. Najarian RM, Sullivan LM, Kannel WB, et al. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med 2006:166:106 111.
36. Setji TL, Brown AJ. Polycystic ovary syndrome: diagnosis and treatment. Am J Med 2007:120:128 132.
37. Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006:91:48 53.
38. Dokras A, Bochner M, Hollinrake E, et al. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005:106:131 137.
39. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004:110:227 239.
40. Grundy SM, Brewer HB Jr., Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004:109:433 438.
41. Grundy SM, Hansen B, Smith SC Jr., et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004:109:551 556.
42. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005:112:2735 2752.
43. International Diabetes Federation (IDF). The IDF consensus worldwide definition of the metabolic syndrome. In: http://www.idf.org/metabolic_syndrome. Brussels, 2006.
44. Pi-Sunyer X. The metabolic syndrome: how to approach differing definitions. Med Clin North Am 2007:91:1025 1040, vii.
45. Standards of medical care in diabetes - 2006. Diabetes Care 2006:29 (Suppl. 1 S4 S42.
46. Rajala MW, Scherer PE. Minireview: the adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003:144:3765 3773.
47. Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev 2006:27:762 778.
48. Bjorbaek C, Kahn BB. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res 2004:59:305 331.
49. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001:86:1930 1935.
50. Lehrke M, Reilly MP, Millington SC, et al. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004:1:e45.
51. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993:259:87 91.
52. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005:115:1111 1119.
53. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006:116:1793 1801.
54. Monzillo LU, Hamdy O, Horton ES, et al. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res 2003:11:1048 1054.
55. O'Brien KD, Brehm BJ, Seeley RJ, et al. Diet-induced weight loss is associated with decreases in plasma serum amyloid a and C-reactive protein independent of dietary macronutrient composition in obese subjects. J Clin Endocrinol Metab 2005:90:2244 2249.
56. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 2000:49:677 683.
57. Levin MC, Monetti M, Watt MJ, et al. Increased lipid accumulation and insulin resistance in transgenic mice expressing DGAT2 in glycolytic (type II) muscle. Am J Physiol Endocrinol Metab 2007:293:E1772 E1781.
58. Gentile M, Panico S, Jossa F, et al. Small dense LDL particles and metabolic syndrome in a sample of middle-aged women. Findings from Progetto Atena. Clin Chim Acta 2008:388:179 183.
59. Guyton JR, Klemp KF. Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 1996:16:4 11.
60. Ginsberg HN, Ngai C, Wang XJ, et al. Increased production rates of LDL are common in individuals with low plasma levels of HDL cholesterol, independent of plasma triglyceride concentrations. Arterioscler Thromb 1993:13:842 851.
61. Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes 1996:45 (Suppl. 3 S27 S30.
62. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000:106:453 458.
63. Jeppesen J, Hein HO, Suadicani P, et al. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 1997:17:1114 1120.
64. Ginsberg HN, Zhang YL, Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring) 2006:14 (Suppl. 1 41S 9S.
65. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985:28:412 419.
66. Kahn CR, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 1976:294:739 745.
67. Le Roith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001:24:588 597.
68. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000:105:311 320.
69. Svetkey LP, Harsha DW, Vollmer WM, et al. Premier: a clinical trial of comprehensive lifestyle modification for blood pressure control: rationale, design and baseline characteristics. Ann Epidemiol 2003:13:462 471.
70. Semplicini A, Ceolotto G, Massimino M, et al. Interactions between insulin and sodium homeostasis in essential hypertension. Am J Med Sci 1994:307 (Suppl. 1 S43 S46.
71. ter Maaten JC, Voordouw JJ, Bakker SJ, et al. Salt sensitivity correlates positively with insulin sensitivity in healthy volunteers. Eur J Clin Invest 1999:29:189 195.
72. Higashi Y, Sasaki S, Nakagawa K, et al. Effect of obesity on endothelium-dependent, nitric oxide-mediated vasodilation in normotensive individuals and patients with essential hypertension. Am J Hypertens 2001:14:1038 1045.
73. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993:153:598 615.
74. Miranda PJ, DeFronzo RA, Califf RM, et al. Metabolic syndrome: evaluation of pathological and therapeutic outcomes. Am Heart J 2005:149:20 32.
75. Mancini M, Mattock M, Rabaya E, et al. Studies of the mechanisms of carbohydrate-induced lipaemia in normal man. Atherosclerosis 1973:17:445 454.
76. Ginsberg H, Olefsky JM, Kimmerling G, et al. Induction of hypertriglyceridemia by a low-fat diet. J Clin Endocrinol Metab 1976:42:729 735.
77. Lien LF, Brown AJ, Ard JD, et al. Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension 2007:50:609 616.
78. Lutsey PL, Steffen LM, Stevens J. Dietary intake and the development of the metabolic syndrome: the Atherosclerosis Risk in Communities study. Circulation 2008:117:754 761.
79. Sato F, Tamura Y, Watada H, et al. Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab 2007:92:3326 3329.
80. Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007:30:1374 1383.
81. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002:288:1882 1888.
82. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003:42:1206 1252.
83. Fogli-Cawley JJ, Dwyer JT, Saltzman E, et al. The 2005 Dietary Guidelines for Americans and risk of the metabolic syndrome. Am J Clin Nutr 2007:86:1193 1201.
84. US Department of Health and Human Services and the US Department of Agriculture. Dietary Guidelines for Americans 2005. http://www.healthierus.gov, 2005.
85. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005:142:611 619.
86. Azadbakht L, Mirmiran P, Esmaillzadeh A, et al. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care 2005:28:2823 2831.
87. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003:289:2083 2093.
88. Svetkey LP, Erlinger TP, Vollmer WM, et al. Effect of lifestyle modifications on blood pressure by race, sex, hypertension status, and age. J Hum Hypertens 2005:19:21 31.
89. Rosenson RS. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am Heart J 2008:155:499 e9 16.
90. Ooi EM, Watts GF, Nestel PJ, et al. Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome. J Clin Endocrinol Metab 2008:93:430 437.
91. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000:342:145 153.
92. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002:359:995 1003.
93. Black HR, Davis B, Barzilay J, et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008:31:353 360.
94. Wright JT Jr., Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2008:168:207 217.
95. Corbould A. Effects of spironolactone on glucose transport and interleukin-6 secretion in adipose cells of women. Horm Metab Res 2007:39:915 918.
96. Nagase M, Matsui H, Shibata S, et al. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007:50:877 883.
97. Caprio M, Feve B, Claes A, et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007:21:2185 2194.
98. Frey FJ, Odermatt A, Frey BM. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr Opin Nephrol Hypertens 2004:13:451 458.
99. Lien LF, Angelyn Bethel M, Feinglos MN. In-hospital management of type 2 diabetes mellitus. Med Clin North Am 2004:88:1085 1105, xii.
100. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996:334:574 579.
101. Feinglos MN, Bethel MA. Treatment of type 2 diabetes mellitus. Med Clin North Am 1998:82:757 790.
102. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999:22:925 927.
103. Bray GA. Medical therapy for obesity - current status and future hopes. Med Clin North Am 2007:91:1225 1253, xi.
104. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002:346:393 403.
105. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007:30:753 759.
106. Ahren B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 2007:30:1344 1350.
107. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007:298:194 206.
108. Green JB, Feinglos MN. Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity. Curr Diab Rep 2007:7:369 375.
109. Jones MC. Therapies for diabetes: pramlintide and exenatide. Am Fam Physician 2007:75:1831 1835.
110. Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007:146:477 485.
111. Malozowski S. Exenatide in combination therapy: small study, big market, and many unanswered questions. Ann Intern Med 2007:146:527 528.
112. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008:31:173 175.
113. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005:142:532 546.
114. Snow V, Barry P, Fitterman N, et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005:142:525 531.